• Menu
    • Search
    • Stock Code: 00512.HK
    • About Us
      • Company Profile
      • Company History
      • Enterprise Members
    • Product Center
      • Pharmaceutical Preparations
      • Medical Devices
      • Bio-technology Products and Health Products
      • Specialized Pharmaceutical Raw Materials and Other Products
      • Innovative Pipeline
    • Investor Relations
      • Information Disclosure
      • Corporate Governance
      • Stock Info
      • Contact Information
    • News & Media
      • Corporate News
      • Media Reports
      • Monthly Newsletter
    • Contact Us
      • Contact Information
      • Privacy Protection
    • Language
      • EnglishEnglish
      • 繁体中文繁体中文
      • 简体中文简体中文
  • English English
    • EnglishEnglish
    • 繁体中文繁体中文
    • 简体中文简体中文
  • Stock Code: 00512.HK

Information Disclosure

  • Home
  • Information Disclosure
Contact Us

Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong

ir@chinagrandpharm.com

www.chinagrandpharm.com

Pages Links

Company Profile

Product Center

Investor Relations

News & Media

Stock Info

Contact Us

Privacy

Legal Statement

Recent News
  • First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization of Technological Innovation Pipelines Globally at Full Speed First-mover Advantages in Anti-virus and Anti-infection Area Come into Play

    2020-12-13

  • GP (HK)’s Associate Sirtex Enters into Transactions and Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment and Continues to Propel Global Planning of Technological Innovation

    2020-12-9

© 2021. China Grand Pharmaceutical and Healthcare Holdings Limited All Rights Reserved.